8 analysts have shared their evaluations of R1 RCM RCM during the recent three months, expressing a mix of bullish and bearish perspectives.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
---|---|---|---|---|---|
Total Ratings | 4 | 3 | 1 | 0 | 0 |
Last 30D | 0 | 1 | 0 | 0 | 0 |
1M Ago | 0 | 0 | 0 | 0 | 0 |
2M Ago | 1 | 0 | 0 | 0 | 0 |
3M Ago | 3 | 2 | 1 | 0 | 0 |
Insights from analysts' 12-month price targets are revealed, presenting an average target of $16.75, a high estimate of $20.00, and a low estimate of $15.00. A decline of 1.47% from the prior average price target is evident in the current average.
Understanding Analyst Ratings: A Comprehensive Breakdown
A comprehensive examination of how financial experts perceive R1 RCM is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
---|---|---|---|---|---|
Sean Dodge | RBC Capital | Maintains | Outperform | $19.00 | $19.00 |
Richard Close | Canaccord Genuity | Lowers | Buy | $15.00 | $16.00 |
Sarah James | Cantor Fitzgerald | Maintains | Overweight | $20.00 | - |
Jack Wallace | Guggenheim | Lowers | Buy | $15.00 | $17.00 |
Jailendra Singh | Truist Securities | Maintains | Hold | $16.00 | $16.00 |
Craig Hettenbach | Morgan Stanley | Maintains | Overweight | $17.00 | $17.00 |
Richard Close | Canaccord Genuity | Lowers | Buy | $16.00 | $17.00 |
Daniel Grosslight | Citigroup | Announces | Buy | $16.00 | - |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to R1 RCM. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of R1 RCM compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for R1 RCM's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
To gain a panoramic view of R1 RCM's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.
Stay up to date on R1 RCM analyst ratings.
Get to Know R1 RCM Better
R1 RCM Inc is a provider of technology-driven solutions that transform the patient experience and financial performance of healthcare providers. Its services help healthcare providers generate sustainable improvements in their operating margins and cash flows while also enhancing patient, physician, and staff satisfaction for the customers, Its service offering consists of end-to-end RCM services for health systems, hospitals, and physician groups that provide comprehensive revenue cycle infrastructure to providers, including all revenue cycle personnel, technology solutions, and process workflow. The majority of the revenue comes from the operating fees received.
R1 RCM's Financial Performance
Market Capitalization Analysis: The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.
Revenue Growth: R1 RCM displayed positive results in 3 months. As of 31 March, 2024, the company achieved a solid revenue growth rate of approximately 10.69%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: R1 RCM's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of -5.81%, the company may face hurdles in effective cost management.
Return on Equity (ROE): R1 RCM's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive -1.26% ROE, the company effectively utilizes shareholder equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of -0.65%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: With a below-average debt-to-equity ratio of 0.85, R1 RCM adopts a prudent financial strategy, indicating a balanced approach to debt management.
The Significance of Analyst Ratings Explained
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.